Reconfirmation of newly discovered risk factors of diabetic peripheral neuropathy in patients with type 2 diabetes: A case-control study

Yen-Wei Pai¹, Ching-Heng Lin², Shih-Yi Lin³,⁴, I-Te Lee⁴,⁵,⁶*, Ming-Hong Chang¹,⁷*

¹ Neurological Institute, Taichung Veterans General Hospital, Taichung, Taiwan, ² Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, ³ Center for Geriatrics and Gerontology, Taichung Veterans General Hospital, Taichung, Taiwan, ⁴ Department of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, ⁵ Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ⁶ Department of Medicine, School of Medicine, Chung Shan Medical University, Taichung, Taiwan, ⁷ Department of Neurology, School of Medicine, National Yang-Ming University, Taipei, Taiwan

* These authors contributed equally to this work.
* cmh50@ms10.hinet.net (MHC); itlee@vghtc.gov.tw (ITL)

Abstract

Aims
The aim of the present study was to investigate the major determinants of diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes (T2D), considering the traditional and newly discovered risk factors, including hypoglycaemia and glycemic variability.

Methods
This retrospective case-control study was conducted in a tertiary care hospital in Taiwan. A total of 2,837 patients with T2D were recruited, medical history and biochemical data were obtained, and patients were screened for DPN using the Michigan Neuropathy Screening Instrument (MNSI). DPN was defined as an MNSI exam score > 2. A stepwise selection of variables was used based on the Akaike Information Criterion (AIC) and the Schwarz Criterion (SC). Multivariate analysis was performed using the identified variables obtained from the stepwise selection.

Results
Among the recruited patients, 604 (21.3%) were found to have DPN. 275 patients with DPN were selected because of longer follow up period before enrollment and complete data of glycemic parameters, and were paired with 351 patients with T2D without DPN and matched for age, gender, and diabetes duration. The results of the stepwise selection showed that the presence of moderately and severely increased albuminuria yielded the lowest values of AIC and SC, which indicate the best predictive performance. Multivariate analysis demonstrated that moderately and severely increased albuminuria and greater long-term glycemic
variability significantly increased the risk of DPN, with a corresponding odds ratio of 1.85 and 1.61 (95% confidence intervals of 1.25–2.73 and 1.02–2.55, respectively), after adjusted for hypoglycaemia and types of diabetes treatment.

Conclusions

Albuminuria is a potent predictor of DPN, and greater long-term glycemic variability is clearly associated with DPN in adults with T2D. These findings indicate that, in addition to achieve average blood glucose control, screening for albuminuria and reducing blood glucose fluctuations might be useful for improving diabetic microvascular complications.

Introduction

Diabetic peripheral neuropathy (DPN) is a common and debilitating microvascular complication of diabetes, affects nearly half of patients with diabetes after 10 years, increases the risk of ulcerations and lower extremities amputations, and has a deleterious impact on quality of life [1]. Older age, longer diabetes duration, poor glycemic control, hypertension, and dyslipidemia are well-known risk factors of DPN. Glycated hemoglobin (HbA1c) is considered the gold standard and surrogate end-point for glycemic control in the long-term diabetes management. However, many results from clinical trials and systematic reviews suggest that enhanced sugar control for targeting normal HbA1c levels does not significantly reduce DPN in patients with type 2 diabetes (T2D) but increases the risk of severe hypoglycemic episodes [2]. Given the high prevalence and limited therapeutic options, it is important to identify potentially modifiable risk factors of DPN in individuals with T2D [3]. Hypoglycemia or glycemic variability, an important aspect of overall glycemic control, may provide an additional or better value in predicting diabetic complications than the average glycemic measure. A number of studies suggested that long-term glycemic variability, as determined by visit-to-visit variations in fasting plasma glucose (FPG) or HbA1c, is a potent indicator in patients with T2D [4, 5]. In addition, recent evidence has shown that previous hypoglycemic events requiring hospitalization or visits to emergency department were associated with an increased risk of DPN, independent of HbA1c levels [6]. To date, no study has yet evaluated which of these newly discovered and previously found risk factors play a key role in DPN. Therefore, the aim of this study was to investigate the major determinants of DPN in a large cohort of adult patients with T2D.

Materials and methods

Study design and participants

This retrospective case-control study enrolled type 2 diabetes patients aged 20 years and older from the outpatient department of a tertiary care teaching hospital in Taiwan between January and October 2013. The diagnosis of T2D was established according to the criteria of American Diabetes Association (ADA). Patients with type 1 diabetes, gestational diabetes mellitus, follow-up duration < 1 year, and less than two records of blood biochemical measurements within six months before enrolment were excluded from this study. Finally, a total of 2,837 patients with T2D were recruited. Prior to analysis, patient data was anonymized by the computer. The study protocol was reviewed and approved by the Institutional Review Board of Taichung Veterans General Hospital (CE-17217B).
Anthropometric and biochemical measurements

Upon entry into our study, all participants completed a standardized, computerized questionnaire administered by a case management nurse that was used to record their previous or current disease status, medication use, and lifestyle habits and also underwent anthropometric measurements, including height and weight (both recorded using a calibrated balance with a stadiometer). Body mass index (BMI) was calculated by dividing the weight in kilograms by the height in squaremeters ($\text{kg/m}^2$).

The participants’ laboratory tests and medications were obtained from hospital records and were repeated every three months. After overnight fasting, blood was drawn from an antecubital vein in the morning and sent for collection for biomarkers, such as serum creatinine, fasting plasma glucose ([FPG] using the standard enzymatic method), HbA1c (using high-performance liquid chromatography), and lipid profiles, including triglycerides, high- and low-density lipoprotein cholesterol levels (using the standard enzymatic method). Based on the Modification of Diet in Renal Disease equation, the estimated glomerular filtration rate (eGFR) was calculated as $186 \times \left( \text{serum creatinine concentration [mg/dL]} \right)^{-1.154} \times \left( \text{age [year]} \right)^{-0.203} (\times 0.742, \text{if female})$ [7]. Early morning spot urine samples were obtained to measure urinary albumin and creatinine using the immunoturbidimetric technique and standard enzymatic method (Wako, Osaka, Japan). Urinary albumin-to-creatinine ratio (UACR) was calculated as urinary albumin (mg) divided by urinary creatinine (g). A UACR of $\leq 30 \text{ mg/g}$ was defined as moderately and severely increased albuminuria [8].

Fasting samples for a glucose assay were obtained every three months during the follow-up period preceding enrollment. The long-term glycemic variability was estimated from the coefficient of variation (CV) of the quarterly visit-to-visit FPG [9, 10]. The study participants were grouped into quartiles according to FPG-CV, and those with a fourth quartile of FPG-CV ($\geq 27.0$ in our cohort) were considered to have greater glycemic variations.

Diagnosis of hypoglycemia and comorbidities

Hypoglycemia was identified by the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 251.0, 251.1, and 251.2 as the main diagnoses during emergency department visits or hospitalization in accordance with the ADA diagnosis. The ADA’s definition of severe hypoglycemia is severe cognitive impairment caused by hypoglycemia, requiring external assistance for recovery without a specific glucose threshold [11]. Hypoglycemic episodes from January 1, 2000 to December 31, 2012 were included. Patients with ICD-9-CM codes of 270.3 (leucine-induced hypoglycemia), 775.6 (neonatal hypoglycemia), and 775.0 (hypoglycemia in an infant born to a diabetic mother) were excluded from this study.

Any claims, including a history of hypertension (ICD-9-CM codes 401–405), cardiovascular disease (390–438), ischemic heart disease (410–414), chronic kidney disease (582–583) or chronic liver disease (571), for both in and outpatient records between 2010 and 2012 were considered as comorbidities based on the listed codes.

Assessment of DPN

DPN was determined using the second component of Michigan Neuropathy Screening Instrument (MNSI), a structured examination of the feet involving an inspection of the feet and evaluation of fine touch (using Semmes-Weinstein 5.07 10-g monofilament), distal vibration perception (using 128-Hz tuning fork), and ankle reflexes. An MNSI exam (MNSIE) score $> 2$ is diagnostic for DPN. The aforementioned examinations in our study were performed by the same trained and certified investigator in order to control for inter-rater reliability. The
investigator only recorded positive (absent response) or negative (normal or diminished response) in items 3–5 (fine touch, vibration perception and ankle reflexes). If more than two positive responses recorded, DPN was determined, with the threshold defined by prior validation studies [12, 13].

Statistical analysis
Continuous variables were described as the mean ± standard deviation (SD), numbers with percentages, or median values with interquartile range. The categorical variables were analysed using Fisher’s exact test or the χ² test, and the continuous variables were analysed using the Student’s t-test or analysis of variance (ANOVA). The CVs of the FPG measurements from outpatient visits before the enrollment of each patient into the study were calculated for those with more than two FPG measurements within six months of enrollment. When considering the effect of the number of visits on CV, the CV of FPG was divided by square root of the ratio of total visits to total visits minus one [4, 14].

A stepwise selection method was performed in order to obtain the best model from a set of predictor variables. Akaike Information Criterion (AIC) and Schwarz Criterion (SC) were used to compare the predictive performance of each model with lower values indicating better predictive performance. The most suitable model was selected as the best model. AIC and SC were both criteria for model selection among a finite set of models, and both of them can be derived from a model’s likelihood function and resulting maximum likelihood estimate. The AIC asymptotically selects the model that minimizes the mean squared error of prediction and also minimizes the maximum possible risk in finite sample size. The SC is consistent in model selection, which could select the true model as the sample size grows as long as the true model is among the candidate models being considered [15]. We used both criteria to test the consistency in these circumstances, whether the true model is in the candidate model set, and also to increase the reliability of our results pertaining to stepwise selection.

A multiple logistic regression analysis was performed using the identified independent variables, and the odds ratios (ORs) between the comparison groups were obtained with 95% confidence intervals (CIs). Statistical significance was defined as a 2-tailed p value < 0.05. Statistical analyses were carried out using SAS statistical software version 9.4 for Windows (SAS Institute Inc., Cary, NC).

Results
Baseline characteristics
Among the recruited patients, 604 (21.3%) were found to have DPN. 275/604 participants with DPN were further selected because of longer follow up period before enrollment and complete data of FPG and HbA1c testing. 351 non-DPN controls were selected and matched for age, gender and duration of diabetes. Table 1 presents the demographic and clinical characteristics grouped according to the DPN status. The mean age of the study population was 72.9 ± 10.5 years, and 53.2% were men. The mean duration of diabetes was 15.4 ± 8.6 years. The majority of participants (97.7%) were treated with pharmacological therapy for diabetes, and 28.4% were treated with insulin (alone or in combination with oral antidiabetic drug). The biochemical parameters were mean values over the follow-up period before enrollment, and the mean FPG and HbA1c level were 141.2 ± 43.4 mg/dL and 7.4 ± 1.4% (57 ± 15.3 mmol/mol), respectively. The values for each quartile of FPG-CV were ≤ 12.3, 12.3–18.2, 18.2–27.0, and > 27.0. On the basis of the univariate analysis, insulin use (P = 0.001), prior severe hypoglycemic episode(s) (P = 0.008), greater FPG-CV (P < 0.001), higher creatinine levels (P = 0.001), lower GFR (P = 0.001), the presence of albuminuria (P < 0.001), and larger amounts of albuminuria
| Variables                          | Total (n = 626) | Without DPN (n = 351) | With DPN (n = 275) | P       |
|------------------------------------|----------------|-----------------------|--------------------|---------|
| Age, years, mean (SD)              | 72.9 (10.5)    | 72.5 (10.4)           | 73.5 (10.7)        | 0.243   |
| Male, n (%)                        | 333 (53.2)     | 186 (53.0)            | 147 (53.5)         | 0.908   |
| Smoking, n (%)                     | 28 (4.5)       | 17 (4.8)              | 11 (4.0)           | 0.612   |
| Alcohol drinking, n (%)            | 14 (2.2)       | 8 (2.3)               | 6 (2.2)            | 0.566   |
| Height, cm, mean (SD)              | 161.0 (8.3)    | 160.8 (8.2)           | 161.3 (8.5)        | 0.424   |
| Weight, kg, mean (SD)              | 65.4 (12.5)    | 65.2 (11.5)           | 65.6 (13.7)        | 0.683   |
| Body mass index, kg/m², mean (SD)  | 25.1 (3.9)     | 25.2 (3.7)            | 24.8 (3.9)         | 0.935   |
| Diabetes duration, years, mean (SD)| 15.4 (8.6)     | 15.1 (8.1)            | 15.9 (9.1)         | 0.294   |
| Diabetes treatment, n (%)          |                |                       |                    |         |
| No medication                      | 13 (2.3)       | 6 (1.9)               | 7 (2.8)            | 0.001   |
| OAD only                           | 393 (69.3)     | 244 (76.3)            | 149 (60.3)         |         |
| Insulin only                       | 56 (9.9)       | 26 (8.1)              | 30 (12.1)          |         |
| Insulin + OAD                      | 105 (18.5)     | 44 (13.8)             | 61 (24.7)          |         |
| Duration of insulin use, years, mean (SD) | 5.5 (4.7) | 5.6 (5.3)              | 5.5 (4.3)         | 0.925   |
| Hypertension, n (%)                | 530 (84.7)     | 291 (82.9)            | 239 (86.9)         | 0.168   |
| Cardiovascular disease, n (%)      | 568 (90.7)     | 314 (89.5)            | 254 (92.4)         | 0.214   |
| Ischemic heart disease, n (%)      | 266 (42.5)     | 141 (40.2)            | 125 (45.5)         | 0.184   |
| Chronic kidney disease, n (%)      | 58 (9.3)       | 27 (7.7)              | 31 (11.3)          | 0.125   |
| Chronic liver disease, n (%)       | 238 (38.0)     | 144 (41.0)            | 94 (34.2)          | 0.080   |
| Hypoglycemia, n (%)                | 35 (5.6)       | 12 (3.4)              | 23 (8.4)           | 0.008   |
| 1                                  | 25 (4.0)       | 9 (2.6)               | 16 (5.8)           | 0.027   |
| 10                                 | 10 (1.6)       | 3 (0.9)               | 7 (2.5)            |         |
| Hypertensive drug treatment, n (%) | 516 (82.4)     | 282 (80.3)            | 234 (85.1)         | 0.121   |
| Lipid-lowering agent treatment, n (%) | 391 (62.5) | 228 (65.0)            | 163 (59.3)         | 0.145   |
| FPG, mg/dL                         | 141.2 (43.4)   | 142.7 (41.7)          | 139.3 (45.4)       | 0.347   |
| Hba1C, % (mmol/mol)                | 7.4±1.4 (57±15.3) | 7.4±1.3 (57±14.2) | 7.5±1.4 (58±15.3) | 0.592   |
| Number of FPG testing, n, mean (SD)| 20.7 (15.1) | 20.2 (14.9)            | 21.3 (15.2)        | 0.364   |
| Number of Hba1c testing, n, mean (SD)| 32.3 (11) | 32.9 (10.5)             | 31.6 (11.5)        | 0.119   |
| Follow up duration of FPG testing, years, mean (SD) | 4.0 (1.8) | 4.1 (1.8)              | 3.9 (1.8)          | 0.151   |
| Follow up duration of Hba1c testing, years, mean (SD) | 8.0 (2.1) | 8.2 (2.0)              | 7.7 (2.1)          | 0.002   |
| FPG-CV, %, mean (SD)               | 20.3 (10.5)    | 18.3 (9.7)            | 22.8 (11.0)        | < 0.001 |
| ≤ 12.3                             | 158 (25.2)     | 112 (31.9)            | 46 (16.7)          | < 0.001 |
| 12.3 to 18.2                       | 154 (24.6)     | 93 (26.5)             | 61 (22.2)          |         |
| 18.2 to 27.0                       | 159 (25.4)     | 84 (23.9)             | 75 (27.3)          |         |
| > 27.0, n (%)                      | 155 (24.8)     | 62 (17.7)             | 93 (33.8)          |         |
| Creatinine, mg/dL, mean (SD)       | 1.3 (1.0)      | 1.2 (0.8)             | 1.5 (1.2)          | 0.001   |
| GFR, ml/min/1.73 m², mean (SD)     | 64.8 (28.3)    | 68.6 (26.9)           | 60.2 (29.3)        | 0.001   |
| UACR, mg/g, mean (SD)              | 297.8 (841.2)  | 186.3 (654)           | 436.2 (1012.1)     | 0.001   |
| ≥ 30, n (%)                        | 251 (49.5)     | 115 (40.9)            | 136 (60.2)         | < 0.001 |
| LDL-C, mg/dL                       | 97.8 (27.9)    | 98.4 (27.7)           | 97.0 (28.2)        | 0.558   |
| HDL-C, mg/dL                       | 50.8 (14.6)    | 50.8 (14.7)           | 50.9 (14.5)        | 0.937   |

(Continued)
were significantly associated with DPN. There were no differences in smoking, alcohol consumption, height, weight, BMI, mean FPG, HbA1c levels or lipid profiles between patients with and without DPN.

Results of stepwise selection of variables

Table 2 shows the results of the stepwise selection of variables based on AIC and SC. A higher level of HbA1c (defined as HbA1c \( \geq 7\% \)) was used as baseline, and variables with lower AICs and SCs were selected. The selected variables were moderately and severely increased albuminuria (AIC 682.186, SC 690.643), type of diabetes treatment (AIC 767.708, SC 785.069), greater FPG-CV (AIC 841.057, SC 849.936), and prior severe hypoglycemic event(s) (AIC 855.450, SC 864.329). The presence of moderately and severely increased albuminuria showed the lowest AIC and SC scores, which indicates the best performance of risk prediction for a given outcome.

Adjusted ORs of DPN using the identified variables

Based on the results of stepwise selection, Table 3 shows the multivariate adjusted ORs and 95% CIs of DPN in patients with T2D. After controlling the competing risk factors, multivariate logistic regression analysis showed that the presence of prior severe hypoglycemic events (OR 2.32, 95% CI 0.96–5.59), moderately and severely increased albuminuria (OR 1.98, 95% CI 1.38–2.85), and greater glycemic variability (OR 1.78, 95% CI 1.02–2.55) were associated with increased DPN risk. After further adjustment for type of diabetes treatment, the presence of moderately and severely increased albuminuria and greater glycemic variability remained

### Table 2. Results of stepwise selection of variables based on AIC and SC.

| Model-X variables          | AIC     | SC    |
|---------------------------|---------|-------|
| UACR (mg/g) (< 30/ \( \geq 30\)) | 682.186 | 690.643 |
| Type of diabetes treatment | 767.708 | 785.069 |
| FPG-CV (< 27.0/ \( > 27.0\)) | 841.057 | 849.936 |
| Hypoglycemia (No/Yes)     | 855.450 | 864.329 |
| HbA1c (%) (< 7/ \( \geq 7\)) | 862.568 | 871.446 |

AIC: Akaike Information Criterion; CV: coefficient of variation; FPG: fasting plasma glucose; HbA1c: glycated hemoglobin; SC: Schwarz Criterion; UACR: urinary albumin-to-creatinine ratio.
significantly correlated with DPN with a corresponding ORs of 1.85 and 1.61 (95% CI 1.25–2.73 and 1.02–2.55, respectively).

Discussion

This is the first large-scale study to report the major determinants associated with the risk of DPN in adult patients with T2D, considering the newly discovered risk factors, including both hypoglycemia and glycemic variability. The present study demonstrated that the presence of moderately and severely increased albuminuria is an important predictor of DPN, and greater glycemic variability as defined by FPG-CV is a risk factor for DPN in adults with T2D.

It is widely accepted that older age, longer diabetes duration, and poor glycemic control are important risk factors in DPN development [5]. However, multiple clinical trials have revealed that strict blood sugar management, using the average glycemic measure (HbA1c) as therapeutic target, does not stop onset and progression of DPN in patients with T2D [2]. This suggests that additional factors other than mean HbA1c values may account for increased neuropathy risk. Besides, hyperglycemia, hypoglycaemia, and glycemic variations also contribute to the net balance of glycemic status and have emerged as measure of glycemic control. Recent results have suggested that hypoglycemia or glycemic variability may be an additional or better glycemic parameter than mean HbA1c levels for assessing the risk of microvascular and macrovascular complications in patients with diabetes, including DPN [6, 14, 16].

In order to identify the most potent modifiable risk factor for DPN, we conducted a case-control study (matched for non-modifiable risk factors, including age, gender, and diabetes duration), and we took into account the recently found risk factors. Based on the univariate analysis, only the presence of prior severe hypoglycemic episode, larger amounts of albuminuria, higher level of creatinine, lower eGFR, greater FPG-CV, and modalities for treatment were significantly associated with DPN. The selected variables based on stepwise selection were moderately and severely increased albuminuria, greater FPG-CV, prior severe hypoglycaemic episode(s), and types of diabetes treatment. After controlling the competitive factors in the multivariate analysis, moderately and severely increased albuminuria, and greater FPG-CV remained independently correlating with DPN. The presence of prior severe hypoglycemic episodes showed a trend toward increased risk of DPN but were not significant. The possible explanation indicates that hypoglycemia is one of the most common adverse reactions of

| Variable     | Adjusted OR a | 95% CI       | P   | Adjusted OR b | 95% CI       | P   |
|--------------|---------------|--------------|-----|---------------|--------------|-----|
| UACR < 30    | 1.00          | —            | —   | 1.00          | —            | —   |
| UACR ≥ 30    | 1.98          | (1.38–2.85)  | < 0.001 | 1.85          | (1.25–2.73)  | 0.002 |
| FPG-CV ≤ 27.0| 1.00          | —            | —   | 1.00          | —            | —   |
| FPG-CV > 27.0| 1.78          | (1.18–2.70)  | 0.006 | 1.61          | (1.02–2.55)  | 0.043 |
| Hypoglycemia |               |              |     |               |              |     |
| No           | 1.00          | —            | —   | 1.00          | —            | —   |
| Yes          | 2.32          | (0.96–5.59)  | 0.060 | 1.64          | (0.65–4.17)  | 0.295 |

CI: confidence interval; CV: coefficient of variation; DPN: diabetic peripheral neuropathy; FPG: fasting plasma glucose; OR: odds ratio; UACR: urinary albumin-to-creatinine ratio.

aModel I: Adjusted for UACR (< 30, ≥ 30), FPG-CV (≤ 27.0, > 27.0), hypoglycemia (No, Yes).
bModel II: Based on Model I, additionally adjusted for type of diabetes treatment.
diabetes therapy. Excessive lowering of blood glucose level during diabetes therapy, which frequently involves augmenting insulin effects directly or indirectly, might cause hypoglycemia and sometimes severe hypoglycemia. Therefore, there are strong correlations between hypoglycemia and modalities for treatment, and the significance might considerably attenuate if adjusted for both variables.

Our findings are crucial for the clinical management of diabetes. Screening diabetic patients for albuminuria may help identify individuals who are at increased risk of DPN. Besides, controlling only HbA1c without controlling glucose variations may not be sufficient. Avoidance of hypoglycemic episodes over time should be a goal in preventing development or halting of DPN progression.

DPN pathogenesis is complex and multi-factorial, involving complicated mechanisms, including excess glycolysis, augmented flux through the polyol pathway, enhanced activity of hexosamine pathway, overproduction of precursors of advanced glycation end products, and impaired insulin signaling that lead to oxidative stress generation and inflammatory injury [1]. Albuminuria, the pathological excretion of urinary albumin, reflects a state of vascular inflammation and generalized endothelial dysfunction causing further damage to microvessels. Several studies have demonstrated that albuminuria is not only an early marker of renal injury but also be a useful target for therapy because it is potentially reversible. The more albuminuria is lowered, the more beneficial renal and cardiovascular outcome is obtained [17, 18].

Increasing evidence shows that many of the cellular processes that occur with hyperglycemic spikes also occur in hypoglycemic troughs [19]. Several animal studies have reported that experimental hypoglycemia induced by injections of excess insulin in rats resulted in Wallerian-type axonal degeneration [20]. The presently available data suggest that hypoglycemia, rather than hyperinsulinemia, is responsible for insulin-induced hypoglycemic peripheral neuropathy. Evidence suggests that insulin is beneficial for peripheral nervous system (PNS) function and serves a promoter of axonal regeneration after injury, whereas hypoglycemia during normal insulin levels causes axonal degeneration in the PNS. Depletion of energy within neurons due to hypoglycemia may result in both altered intra-neural concentrations of various metabolites, leading to axonal degeneration and myelin breakdown in Schwann cells. Endoneurial microvascular changes caused by local ischemia may also play a role in PNS damage [21]. In addition, oscillating glucose has been shown to be more detrimental to endothelial function than inflammatory cytokines and oxidative stress than chronic sustained hyperglycemic levels, which are involved in the pathogenesis of microvascular complications [22].

The strengths of our study include the large sample size, standardized data collection procedures, detailed information available on possible confounding factors, laboratory test values, and diabetes treatment. Another strength is the use of the validated clinical screening instrument (MNSI), which is sensitive, specific, non-invasive, and easy to administer. There were limitations. First, causality cannot be inferred due to cross-sectional design. Second, the DPN diagnosis was not confirmed by electrophysiological tests, such as nerve conduction studies. Third, the present study included only Chinese population with T2D, so the result might be not representative of all patients with diabetes mellitus. Fourth, the influence of minor hypoglycemic episodes on the risk of DPN was not assessed in this study.

Conclusions

In conclusion, our study shows that the presence of moderately and severely increased albuminuria, defined by a UACR of ≥30mg/g, is a strong predictor of DPN. Greater long-term glycemic variability determined by FPG-CV is clearly associated with DPN in adults with T2D. Longitudinal studies are required to confirm the merit of albuminuria or glycemic variability...
for identifying individuals at increased risk for DPN within the large population of patients with T2D.

**Supporting information**

**S1 Appendix. Part of our dataset.** Some information of the participants was not provided due to patient privacy.

(XLS)

**Acknowledgments**

The authors would like to thank the Biostatics Taskforce of Taichung Veterans General Hospital for statistical support. This study is based in part on data from the Taichung Veterans General Hospital Research Database as managed by the Clinical Informatics Research & Development Center of Taichung Veterans General Hospital (registered number F17069). The interpretation and conclusions contained herein do not represent those of Taichung Veterans General Hospital. This research received a grant from Taichung Veterans General Hospital (TCVGH 1083404C), but nothing from commercial or not-for-profit sectors.

**Author Contributions**

**Conceptualization:** Yen-Wei Pai, I-Te Lee, Ming-Hong Chang.

**Data curation:** Yen-Wei Pai, Shih-Yi Lin, I-Te Lee, Ming-Hong Chang.

**Formal analysis:** Yen-Wei Pai, Ching-Heng Lin.

**Investigation:** Yen-Wei Pai, Shih-Yi Lin, I-Te Lee, Ming-Hong Chang.

**Methodology:** Yen-Wei Pai, Ching-Heng Lin, Shih-Yi Lin, I-Te Lee, Ming-Hong Chang.

**Supervision:** Ming-Hong Chang.

**Validation:** Ching-Heng Lin, Ming-Hong Chang.

**Writing – original draft:** Yen-Wei Pai.

**Writing – review & editing:** Yen-Wei Pai, I-Te Lee, Ming-Hong Chang.

**References**

1. Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012; 11(6):521–534. https://doi.org/10.1016/S1474-4422(12)70065-0 PMID: 22608666

2. Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev. 2012;(6):CD007543. https://doi.org/10.1002/14651858.CD007543.pub2 PMID: 22696371

3. Roustit M, Loader J, Deusenbery C, Baltzis D, Veves A. Endothelial Dysfunction as a Link Between Cardiovascular Risk Factors and Peripheral Neuropathy in Diabetes. J Clin Endocrinol Metab. 2016; 101:3401–3408. https://doi.org/10.1210/jc.2016-2030 PMID: 27399351

4. Yang CP, Li CI, Liu CS, Lin WY, Hwang HY, Yang SY, et al. Variability of fasting plasma glucose increase risks of diabetic polyneuropathy in T2DM. Neurology. 2017; 88: 944–951. https://doi.org/10.1212/WNL.0000000000003682 PMID: 28179465

5. Su JB, Zhao LH, Zhang XL, Cai HL, Huang HY, Xu F, et al. HbA1c variability and diabetic peripheral neuropathy in type 2 diabetic patients. Cardiovasc Diabetol. 2018; 17:47. https://doi.org/10.1186/s12933-018-0693-0 PMID: 29598819

6. Pai YW, Lin CH, Lee IT, Chang MH. Hypoglycemic episodes and risk of diabetic peripheral neuropathy in patients with type 2 diabetes. Diabetes Metab. 2017 Nov 6. pii: S1262–3636(17)30521-9.
7. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014; 63:713–735. https://doi.org/10.1053/ajkd.2014.01.416 PMID: 24647050

8. American Diabetes Association. 10. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2018. Diabetes Care. 2018; 41(Suppl 1):S105–S118. https://doi.org/10.2337/dc18-S010 PMID: 29223831

9. Lee CL, Sheu WH, Lee IT, Lin SY, Liang WM, Wang JS, et al. Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes. Diabetes Metab. 2017 Oct 9. pii: S1262–3636(17)30512-8.

10. Monnier L, Colette C, Owens D. Glucose variability: Do we have to revisit the profusion of definitions to avoid confusion? Diabetes Metab. 2017 Nov 16. pii: S1262–3636(17)30545-1.

11. American Diabetes Association. Glycemic targets. Sec. 6. In Standards of Medical Care in Diabetes—2017. Diabetes Care. 2017; 40(Suppl. 1):S48–S56. https://doi.org/10.2337/dc17-S009 PMID: 27979893

12. Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012; 29: 937–944. https://doi.org/10.1111/j.1464-5491.2012.03644.x PMID: 22417277

13. Jaiswal M, Lauer A, Martin CL, Bell RA, Divers J, Dabelea D, et al. Peripheral neuropathy in adolescents and young adults with type 1 and type 2 diabetes from the SEARCH for Diabetes in Youth follow-up cohort: a pilot study. Diabetes Care. 2013; 36:3903–3908. https://doi.org/10.2337/dc13-1213 PMID: 24144652

14. Pai YW, Lin CH, Lee IT, Chang MH. Variability of fasting plasma glucose and the risk of painful diabetic peripheral neuropathy in patients with type 2 diabetes. Diabetes Metab. 2018; 44:129–134. https://doi.org/10.1016/j.diabet.2018.01.015 PMID: 29459007

15. Vrieze SI. Model selection and psychological theory: a discussion of the differences between the Akaike information criterion (AIC) and the Bayesian information criterion (BIC). Psychol Methods. 2012; 17:228–243. https://doi.org/10.1037/a0027127 PMID: 22309957

16. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010; 12:288–298. https://doi.org/10.1111/j.1463-1326.2009.01160.x PMID: 20380649

17. Thoenes M, Bramlage P, Khan BV, Schieffer B, Kirch W, Weir MR. Albuminuria: pathophysiology, epidemiology and clinical relevance of an emerging marker for cardiovascular disease. Future Cardiol. 2007; 3: 519–524. https://doi.org/10.2217/14796678.3.5.519 PMID: 19804307

18. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl. 2004;(92):S2–6. https://doi.org/10.1111/j.1523-1755.2004.09201.x PMID: 15485410

19. Razavi Nematoohlaki L, Kitabchi AE, Stentz FB, Wan JY, Larjani BA, Tehrani MM, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. Metabolism. 2008; 58:443–448. https://doi.org/10.1016/j.metabol.2008.01.018 PMID: 19303962

20. Potter CG, Sharma AK, Farber MO, Peterson RG. Hypoglycemic neuropathy in experimental diabetes. J Neurol Sci. 1988; 88:293–301. PMID: 3225627

21. Jensen VF, Melck AM, Begh IB, Lykkesfeldt J. Effect of insulin-induced hypoglycaemia on the peripheral nervous system: focus on adaptive mechanisms, pathogenesis and histopathological changes. J Neuroendocrinol.2014; 26:482–496. https://doi.org/10.1111/jne.12170 PMID: 24921897

22. Ceriello A, Esposito K, Piconi L, Inhat MA, Thorpe JE, Testa R, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008; 57:1349–1354. https://doi.org/10.2337/db08-0063 PMID: 18299315